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Oxidative stress has been implicated in coronary artery disease (CAD). Malondialdehyde (MDA) is lipid 
peroxidation end product. Bilirubin may act as an antioxidant that suppresses lipid oxidation. The role 
of MDA and antioxidant capacity and their inter-relationship in patients with and without CAD was 
investigated. Thirty-eight consecutive patients with angiographically diagnosed CAD were compared 
with 60 age, and sex-matched controls. The controls had completely normal coronary arteries in 
angiograms. Plasma MDA, serum bilirubin, total homocysteine and total antioxidant capacity (TAC) 
levels were measured. Risk factors of CAD were determined for all subjects using National Cholesterol 
Education Program (NCEP)-Adult Treatment Panel (ATP)-III criteria. Serum MDA and total homocysteine 
concentration were significantly higher, but TAC, total bilirubin and direct bilirubin levels were lower in 
CAD patients when compared to the controls. Age, and sex-adjusted plasma MDA levels had negative 
correlations with TAC (r = -0.30, p = 0.001) and total bilirubin (r = -0.30, p = 0.002) concentrations. In 
multivariate analysis by the multiple logistic regression method, serum MDA was significantly 
associated with CAD (OR = 1.15, 95% CI, 1.25 to 1.82; p < 0.0001)) after adjustment for lipid status 
parameters and traditional risk factors in this study population. Increased serum MDA concentration, as 
a biomarker of lipid peroxidation, low serum bilirubin and antioxidant capacity were observed in 
patients with angiographically defined CAD. The significant inverse correlation of the serum bilirubin 
and MDA levels demands further in-depth investigations to clarify the association between them in the 
development of CAD. 
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homocysteine.  
 
 
INTRODUCTION 
 
It has been suggested that oxidative stress, especially 
oxidative modification of low-density lipoproteins (LDL), 
may play a causative role in the pathogenesis of a variety  
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of vascular diseases including atherosclerosis, hyper-
tension and coronary artery disease (Chisolm and 
Steinberg, 2000; Kaur, 2008). Through the oxidative 
modification hypo-thesis, it is well predicted that oxidized 
LDL contributes to atherosclerosis (Stocker and Keaney, 
2004). Clinical research has used different markers to 
investigate the consequences and complications of lipid 
peroxidation    process.    Thiobarbituric    acid     reactive  
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substances (TBARS) mainly MDA are the end products 
of peroxidation of poly unsaturated fatty acids in the cell 
membranes which accumulate when lipid peroxidation 
increases (Ceconi et al., 1992). These substances have 
the ability to interact with lipoproteins, which are then 
taken up by macrophages, and transformed into foam 
cells that contribute to atherosclerotic plaque develop-
ment and progression of atherogenesis (Cavalca et al., 
2001). Lopresti et al. (2008) has also used TBARS mainly 
MDA to evaluate the role of oxidative stress in patients 
with acute myocardial infarction. So one of the most 
frequently used biomarker providing an indication of the 
overall lipid peroxidation level is the plasma concentration 
of MDA (Nielsen et al., 1997). Hence, a great deal of 
interest has focused on investigating the role of different 
anti oxidants including internal and external to prevent 
the oxidation of lipids in the cell membrane especially the 
oxidation of LDL.  
Bilirubin is now recognized as being a potent anti-
oxidant manufactured by the body. Normal human serum 
bilirubin concentrations are high enough to provide a 
substantial portion of the total known antioxidant capacity 
of serum (Morse and Choi, 2005). The biological actions 
of bilirubin may be especially relevant to the prevention of 
oxidant-mediated cell damage (Kushida et al., 2002). It 
has also been proved that bilirubin at low concentration 
scavenges reactive oxygen species in vitro, thereby 
reducing oxidant-mediated cellular damage and attenuate 
oxidative stress in vivo (Stocker et al., 1987). Neuzil and 
Stocker, (1994) has reported that bilirubin may inhibit 
oxidation of LDL lipids initiated within the lipoprotein core. 
The roles of bilirubin in counteracting oxidative stress 
have been reviewed previously (Abraham et al., 2008).  
Schwertner et al. (1994) first reported a significant 
inverse correlation between bilirubin concentration and 
the prevalence of coronary artery disease (CAD). There 
are evidences showing that serum bilirubin concen-
trations at the upper level of the reference values (0.4 to 
1.2 mg/dl) may provide protection against CAD, whereas 
the lower level indicates increased atherogenesis (Mayer 
et al., 2000). Serum bilirubin level was also suggested as 
a predictive biomarker for long-term outcomes in patients 
with cardiac syndrome X (Huang et al., 2010). Also 
reduced serum levels of bilirubin were associated with a 
higher prevalence of coronary artery disease (Ghem et 
al., 2010) and coronary artery calcification (Muhei et al., 
2009). It has been reported that high plasma concen-
tration of total homocysteine is associated with increased 
in vivo lipid peroxidation in men (Sari et al., 1999). Also 
significant increased plasma concentration of MDA and 
total homocysteine have been observed in the patients 
with CAD (Cavalca et al., 2001). More over the increase 
in the level of plasma MDA has been associated with 
inflammatory markers in patients with coronary artery 
calcification which is a marker of CAD severity Jung et 
al., (2004).   
The aim of our study was to further understand the  role  
 
 
 
 
of plasma MDA and the antioxidant system and their 
inter-relationship in patients with CAD compared with the 
controls. To our knowledge, this is the first study to 
investigate possible correlation of serum bilirubin and 
plasma MDA in patients with angiographically defined 
CAD.  
 
 
MATERIALS AND METHODS 
 
Subjects and definitions 
 
Thirty-eight consecutive patients (22 men and 16 women, mean 
age, 52.47 ± 1.14 years) with CAD were compared with 60 age and 
sex-matched controls (26 men and 34 women, mean age, 50.58 ± 
1.07 years). All these subjects underwent coronary angiography in 
the department of cardiology in Bushehr University of Medical 
Sciences, Iran. The total duration for recruitment of participants of 
the study was three months. In this study, selection of both patient 
and control groups was based on the results of angiography. The 
controls had a history suggestive of angina pectoris but completely 
normal coronary arteries (arteries with no wall irregularity in 
angiograms, Friesinger index = 0). Two well experienced cardio-
logists, unaware of the patients' clinical history and biochemical 
results, visually assessed all angiograms to observe the extent of 
the CAD. Patients with myocardial infarction within the previous 3 
months, renal or hepatic diseases, malignancy, thyroid disease, 
connective tissue diseases were excluded. Fasting serum glucose 
of ≥ 126 mg/dl was defined as diabetes. Hypertension was defined 
as having systolic blood pressure ≥ 140 mmHg and diastolic blood 
pressure ≥ 90 mmHg. We also measured liver enzymes in our 
subjects to separate apparent liver diseases. 
The cut-off points for serum total cholesterol, HDL-cholesterol 
and LDL-cholesterol and serum triglycerides distributions used to 
assign subjects at different levels of risk were those derived from 
the National Cholesterol Education Program guidelines in the 
United States Bethesda, Maryland National Institute of Health 
(http://www.nhlbi.nih.gov/guidlines/cholesterol/,accessed) 10 
December 2007. 
The subjects did not receive antioxidant therapy such as ACE 
inhibiters or vitamin supplements at the time of investigation. All the 
patients and controls signed consent forms, and the procedures 
followed were approved by our institution's responsible committee. 
 
 
Samples and analyses 
 
Following a 12 h fasting period, blood samples were collected by 
venipuncture, and EDTA-plasma and sera were obtained by 
centrifugation and stored at -80°C until they were analyzed. Serum 
bilirubin was measured by a diazo method (Rand and diPasqua, 
1962). Glucose was assayed by the enzymatic method of Pars 
Azmun - co, Iran (intra and interassay coefficients of variation (CVs) 
were 3.2 and 2.95%, respectively).  Serum total cholesterol and 
HDL-cholesterol were measured using enzymatic method of 
cholesterol oxidase, pars Azemoon-CO- Iran, on an autoanalyzer 
(Vital scientific   Selectra 2 Spankeren, Netherlands). Intra and 
interassay CVs for TC and HDL-C were 2.1, 2.4% and 1.5, 1.9%, 
respectively. Serum low density lipoprotein (LDL)-cholesterol was 
calculated using the Friedewald formula. An enzyme immunoassay 
for the determination of total homocysteine in blood was used; the 
quantification limit of the DRG Homocysteine EIA (DRG 
International, Inc. USA) was 1.0 µmol/L with a CV <20%.  
Malondialdehyde was measured by using an improved 
Thiobarbituric Acid reactive substaces (TBARs) based method 
(Manceit and Copeland, 1992). The determination of total 
antioxidative capacity was performed using a commercial Kit from 
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Table 1. General characteristics and some basic biochemical parameters of patients and the controls.  
 
Characteristics and biochemical parameters Patients (n = 38) Control (n = 60) P values 
Age (years) 52.47 ± 1.14 50.58 ±1.07 0.247 
Hypertensive, n (%) 22 (57.9) 25 (41.7) 0.078 
Hyperlipidemia, n (%)   29 (76.3) 24 (40.0) <0.001 
Diabetes, n (%) 12 (31.6) 6 (10.0) 0.008 
Family history of CAD, n (%)  8 (21.0) 8 (13.3) 0.302 
Fasting blood sugar (mg/dl) 157.65 ± 63.52 116.52 ± 4.88 <0.0001 
Total cholesterol (mg/dl) 216.50 ± 13.02 217.01 ± 8.90 0.973 
HDL-Cholesterol (mg/dl) 35.44 ± 1.47 43.24 ± 1.41 <0.0001 
LDL-Cholesterol (mg/dl) 125.47 ± 10.13 191.63 ± 41.79 0.217 
Triglyceride (mg/dl) 249.68 ± 37.78 206.62 ± 8.67 0.261 
AST (IU/L) 15.11 ± 1.93 22.53 ± 3.93 0.153 
ALT (IU/L) 9.72 ± 1.34 16.55 ± 3.54 0.137 
 
Data is presented as mean ± SD, AST: aspartate aminotransferase ,ALT: Alanine aminotransferase  HDL:High density lipoprotein, LDL: Low 
density lipoprotein, CAD: Coronary artery diseas n(%):numbers(percent of subgroup). and P Value is considered as <0. 05.  
 
 
 
BioVision-Co, USA which uses Trolox equivalents to standardize 
the antioxidants.  
 
 
Statistical analyses 
 
The significance of the difference in the results of any two groups 
was determined by Chi-square analysis using 2 × 2 contingency 
tables. A two-tailed t-test was used to compare the mean values 
across groups. Absolute values were presented as mean ± 
standard deviation. 
The correlations between markers of oxidative stress and 
biochemical measurements were evaluated using Pearson’s partial 
correlation while controlling for the effect of age and sex. Multiple 
logistic regression analysis was used to ascertain the associations 
between MDA and CAD. Sex, age, lipid status parameters and 
traditional risk factors were considered as covariates, and CAD as 
the dependent variable. P<0.05 was considered statistically 
significant. Statistical analysis was performed with an IBM computer 
using the SPSS 9.05 statistical software package (SPSS Inc., 
Chicago, IL).  
 
 
RESULTS 
 
Demographic features of the subjects and comparison of 
the patients with CAD and the controls regarding 
cardiovascular risk factors are shown in Table 1. There 
were no significant differences between the two groups 
regarding age, sex, family history of CAD and hyper-
tension. However, the patients with CAD had significantly 
higher history of hyperlipidemia and type 2 diabetes 
mellitus when compared to the controls.  
The lipid profiles of the two groups are presented in 
Table1. Serum HDL-C levels were significantly lower in 
CAD group when compared to the controls. There was no 
significant difference between the two groups regarding 
serum concentration of LDL-C, total cholesterol, trigly-
ceride and liver enzymes (Table 1). Serum homocysteine 
and fasting blood glucose concentrations were signi-
ficantly higher in CAD patients than in the controls (p < 
0.0001). 
The parameters that show oxidative stress and 
antioxidant status are presented in Table 2. Serum MDA 
and total homocysteine levels were significantly higher, 
but TAC, total bilirubin and direct bilirubin values were 
lower in CAD patients when compared to the controls. 
Age, and sex-adjusted serum MDA levels had negative 
correlations with TAC (r = -0.34, p = 0.001), total bilirubin 
(r = -0.30, p = 0.002) and HDL-C (r = -0.25, p = 0.01) 
concentrations. Age, and sex-adjusted serum total 
bilirubin had positive correlations with TAC (r = 0.25, p = 
0.01) and HDL-C (r = 0.22, p = 0.03). There were no 
correlation between MDA and LDL-C, total cholesterol 
and triglyceride levels. But serum total bilirubin had a 
significant negative correlation with homocysteine (r = -
0.25, p = 0.01).  
In multivariate analysis by multiple logistic regression 
method, serum MDA was significantly associated with 
CAD (OR = 1.15, 95% CI, 1.25 to 1.82; p < 0.0001) after 
adjustment for lipid status parameters and traditional risk 
factors in the study population. Likewise, serum total 
bilirubin was negatively associated with CAD (OR = 0.01, 
95% CI, 0.01 to 0.24; p = 0.004). 
 
 
DISCUSSION 
 
The results of this study confirmed the role of oxidative 
stress in patients with angiographically defined CAD and 
discovered an expected inverse correlation of plasma 
MDA and antioxidant system. 
The lipid peroxidation end product, MDA is one of the 
most reliable and widely used indexes of oxidative stress 
(Kaur et al., 2008). The involvement of lipid peroxidation 
in CAD patients was confirmed by the significant increase 
in  the  blood  concentration  of  MDA  in  the  case  group  
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Table 2. Plasma malondialdehyde, total bilirubin, direct bilirubin, antioxidant status and homocysteine levels of the 
study groups. 
 
Blood parameter Patients (n=38) Control (n=60) P value 
Total antioxidant capacity (µmol/L) 131.82 ± 5.27 170.05 ± 4.80 <0.0001 
Malondialdehyde (nmol/mL) 12.19 ± 0.68 5.68 ± 0.45 <0.0001 
Total Bilirubin (mg/dl) 0.48 ± 0.02 0.76 ± 0.03 <0.0001 
Direct Bilirubin (mg/dl) 0.11 ± 0.01 0.17 ± 0.01 0.02 
Homocysteine  (µmol/L)  18.10 ± 1.64 10.63 ± 0.91 <0.0001 
 
The values are shown as mean ± SD and P value is considered as < 0. 05. 
 
 
 
when compared with the controls. Thus, our findings are 
in line with the results of other published studies, 
(Mendis, 1995; Kotur- Stevuljevic, 2006). 
One of the main roles in the prevention of oxidative 
stress has been attributed to endogenous molecules 
such as bilirubin (Neuzil and stocker, 1994). Many 
studies have reported that low serum bilirubin 
concentrations are associated with an increased risk of 
atherosclerosis (Lin et al., 2006). The strength of the 
association is similar to that of smoking, elevated systolic 
blood pressure and low levels of high-density lipoprotein 
(HDL) cholesterol (Rantner, 2008). 
In our study, we also demonstrated an inverse relation-
ship between the presence of CAD and circulatory total 
bilirubin. This might be explained by in vitro findings that 
have shown bilirubin to have antioxidative and cyto-
protective properties (Stocker, 1987; Neuzil and Stocker, 
1994). The mechanism of action of these properties of 
bilirubin could be explained by the role of the enzyme 
heme oxygenase-1 (HO-1). This enzyme catalyzes the 
conversion of heme to biliverdin, carbon monoxide and 
iron. Subsequent to the reaction, biliverdin is converted to 
bilirubin by biliverdin reductase. Biliverdin and bilirubin 
have been shown to act as scavengers of reactive 
oxygen species and so they have anti inflammatory 
effects (Ryer and Choi, 2006). Oxidized LDL is known to 
act as a potent inducer of heme oxygenase-1 (HO-1) in 
vascular cells. In vascular endothelial cells, vascular 
smooth muscle cells, and macrophages, HO-1 is 
markedly up-regulated by oxidized LDL (Abraham and 
Kappas, 2008). The cytoprotective activity of this enzyme 
against oxidative injury and cellular stresses was 
attributable to bilirubin (Morse and Choi, 2005; Idriss, 
2008). Accordingly, low bilirubin concentrations may be 
associated with increase in oxidized lipids and 
lipoproteins which consequently leads to atherogenic 
plaque formation (Mayer, 2000).  
Given the antioxidant capacity of bilirubin, it is plausible 
that we found a strong inverse relationship between 
serum bilirubin concentrations and MDA, which is a 
highly reactive metabolite of free radical induced lipid 
peroxidation. 
There are very limited studies about correlation of 
bilirubin and MDA in ischemic heart disease (Masini, et 
al., 2003; Abraham and Kappas, 2008). Serdar et al. 
(2006) demonstrated that an inverse correlation exists 
between plasma MDA, erythrocyte MDA and delta-MDA 
levels, and most of the antioxidant enzymes and vitamins 
in patients with CAD. This is in accordance with our 
findings that a significant inverse correlation exists 
between serum MDA and total antioxidative capacity.  
Interestingly, we found a strong inverse correlation 
between MDA and HDL-C, and also a significant positive 
correlation between serum total bilirubin and HDL-C in 
this studied population. So our observations confirmed 
the data from previous studies (Kotur- Stevulijevic, 2007; 
Mahparta, 1998). This is to mention that even though in 
our study, there were correlations between serum MDA 
and the parameters including total bilirubin, TAC and 
HDL-C, but the r values were very small.  These 
observations need a mechanistic explanation concerning 
the relationship between oxidative stress and lipoprotein 
particles. 
Our study showed a significant increase in serum 
concentration of homocysteine in the patients with CAD 
than the controls. However, no correlation was found 
between homocysteine and MDA concentration. These 
results agree with those of Cavalca et al. (2001). As a 
limitation, due to the small number of patients, we were 
not able to evaluate the effect of MDA on the severity of 
coronary lesions and stratification of the study groups 
according to the serum bilirubin level could not be done.  
In conclusion, this current study indicates that oxidative 
stress and low antioxidant capacity may be associated 
with the pathogenesis of CAD. The observed strong 
inverse correlation of the serum bilirubin level and MDA 
demands further in-depth investigations to clarify the 
connections of HO-1/bilirubin and reactive metabolites of 
free radical induced lipid peroxidation in the development 
of CAD. It is probable that we will see, in the not too 
distant future, human trials involving the heme oxygenase 
system to combat lipid peroxidation for the management 
of CAD. 
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